Department of Obstetrics and Gynecology, Ankara Dr Zekai Tahir Burak Women Health Teaching and Research Hospital, 7.Cadde 70 A/14, Bahcelievler, 06490 Ankara, Turkey.
Arch Gynecol Obstet. 2011 Apr;283(4):799-804. doi: 10.1007/s00404-010-1434-0. Epub 2010 Mar 24.
To show the efficacy of anti-tumor necrosis factor therapy (etanercept) for treating endometriosis in an experimental model.
A randomized, placebo-controlled, blinded study using rat endometriosis model.
Experimental research center of Ankara Education and Research Hospital.
ANIMAL(S): Twenty-two Wistar female rats.
INTERVENTION(S): After peritoneal implantation of endometrial tissue, rats were randomized to two equal intervention groups: control and etanercept-treated groups. After measuring implant volume, blood and peritoneal fluid samples were obtained. Vehicle treatments of 2 mL saline to rats in control and 0.4 mg/kg etanercept SC once weekly were administered in treatment group. Four weeks later, a third laparotomy was performed to remeasure implant volumes, blood, and peritoneal fluid samples.
MAIN OUTCOME MEASURE(S): To compare spherical volume, peritoneal fluid and serum levels of VEGF, IL-6, and TNF-α between groups.
RESULT(S): There was a significant difference in spherical volume between control [131.0 (60.3-501.2)] and treatment groups [72.8 (31.2-149.6)] (p < 0.025). In etanercept-treated group, a significant difference was found between peritoneal fluid and serum levels of VEGF, IL-6, and TNF-α (p < 0.01).
CONCLUSION(S): These results indicate that etanercept was found to effectively reduce the development of endometriosis.
展示抗肿瘤坏死因子治疗(依那西普)治疗子宫内膜异位症的实验模型中的疗效。
一项随机、安慰剂对照、盲法研究,使用大鼠子宫内膜异位症模型。
安卡拉教育与研究医院的实验研究中心。
22 只 Wistar 雌性大鼠。
在腹膜内植入子宫内膜组织后,将大鼠随机分为两组:对照组和依那西普治疗组。测量植入物体积后,采集血液和腹腔液样本。对照组给予 2 mL 生理盐水,治疗组给予 0.4 mg/kg 依那西普皮下注射,每周一次。四周后,进行第三次剖腹手术,以重新测量植入物体积、血液和腹腔液样本。
比较两组间球形体积、腹腔液和血清中 VEGF、IL-6 和 TNF-α 的水平。
对照组[131.0(60.3-501.2)]和治疗组[72.8(31.2-149.6)]之间的球形体积存在显著差异(p < 0.025)。在依那西普治疗组中,腹腔液和血清中 VEGF、IL-6 和 TNF-α 的水平存在显著差异(p < 0.01)。
这些结果表明,依那西普可有效抑制子宫内膜异位症的发展。